Ozagrel sodium (OKY-046 sodium) is an antiplatelet agent working as a thromboxane A2 synthesis inhibitor. Thromboxane A2 Synthase
[1]. Nakazawa, M., et al., [Research and development of ozagrel, a highly selective inhibitor of TXA2 synthase]. Yakugaku Zasshi, 1994. 114(12): p. 911-33. [2]. Li, S.B., et al., In vitro effect of ozagrel on mushroom tyrosinase. Protein J, 2009. 28(3-4): p. 182-8. [3]. Westphal, M., et al., Selective thromboxane A2 synthase inhibition by OKY-046 prevents cardiopulmonary dysfunction after ovine smoke inhalation injury. Anesthesiology, 2005. 102(5): p. 954-61.